Biomarker Discovery Outsourcing Services Market – By Type, By Service, By Therapeutic Area, By End Use, Global Forecast 2025 – 2034

Biomarker Discovery Outsourcing Services Market Size

The global biomarker discovery outsourcing services market size was valued at around USD 13 billion in 2024 and is estimated to grow at 12.3% CAGR from 2025 to 2034 owing to rising cases of chronic diseases, progress in omics technologies, growth in investments related to research and developments in the pharmaceutical and biotechnology industry, and the growing importance of personalized medicine.
 

The market’s growth is mainly driven by the increasing cases of chronic conditions such as cardiovascular diseases, diabetes, and cancer that necessitates the demand for novel biomarkers for monitoring the treatment, diagnosis, and early detection. As reported by the American Cancer Society, about 611,720 cancer deaths and 2 million new cases are expected in the U.S. in 2024. The rise in cancer cases is increasing the need for novel biomarkers, which is boosting the growth of the market.
 

To address this increased demand, several organizations are adopting outsourcing methodologies. For instance, ESYA Labs collaborated with Alamar Biosciences in December 2024, aiming to  improve the identification and quantification of biomarkers for inflammatory and neurological diseases. Such initiatives are expected to significantly boost the market growth over the forecast period.
 

Biomarker discovery outsourcing services involve contracting the entire process of biomarker discovery, from detection to validation and analysis to specially qualified external contractors. These services enable diagnostic, biotechnology, and pharmaceutical companies to focus on their core processes while outsourcing critical aspects of their research and development processes to experts at well-equipped service providing firms.
 

Biomarker Discovery Outsourcing Services Market Trends

• The increasing focus on cost reduction, resource optimization, and minimizing failure rates is boosting biotechnology and pharmaceutical companies to outsource biomarker discovery. This trend allows these organizations to utilize advanced technologies and external expertise while avoiding substantial long-term expenses associated with in-house operations.
   
• Moreover, the adoption of single-cell analysis technology and CRISPR-based methodologies is increasing the efficiency and accuracy of biomarker discovery processes. These new strategies are enabling precise targeting of certain molecules and accelerating the development of new biomarkers, thus making it feasible for these companies to offshore these sophisticated tasks.
   
• In addition, the penetration of machine learning (ML) and artificial intelligence (AI) into the processes of biomarker discovery is shifting the industry trends. These technologies are enabling the integration of multifaceted biological information which makes validation of the results much more efficient, thus increasing the chances of discovering new biomarkers.
   

Biomarker Discovery Outsourcing Services Market Analysis

Based on type, the market is segmented into predictive biomarkers, prognostic biomarkers, safety biomarkers, surrogate endpoints, and other types. The surrogate endpoints segment dominated the market with the largest revenue share of 49% in 2024 and is expected to grow at a CAGR of 12.1% over the forecast period.
 

• Surrogate markers make clinical trials more efficient by allowing the completion of clinical studies in a fraction of the time, where complex goals like treatment efficacy can be identified much earlier.
   
• Moreover, this segment is being fueled by the increasing use of surrogate endpoints by emerging markets and U.S. FDA for rare diseases and oncology for issuing market access decisions as well as accelerated approvals of new drugs.
   

Based on service, the biomarker discovery outsourcing services market is segmented into genomics biomarker services, proteomics biomarker services, bioinformatics biomarker services, and other biomarker services. The genomics biomarker services segment dominated the market with the largest revenue of USD 5.7 billion in 2024 and is expected to reach USD 18.3 billion by 2032.
 

• The increasing prevalence of several rare genetic conditions such as neurodegenerative disorders, cardiovascular diseases, and chronic ailments like cancer are catalyzing the biomarker service industry. For instance, the Centers for Disease Control and Prevention stated that approximately 1 in every 5 deaths in the U.S. in 2022 were caused by heart diseases, which was about 702,880 deaths. This rising mortality rate is increasing the need for advanced healthcare interventions, which is further propelling the genomics biomarker service industry.
   
• Moreover, investments and initiatives from the national governments and private sectors, such as the UK Biobank and the All of Us Research Program (U.S.) in the biobanks and genomics research sectors are fostering the efforts on discovery and validation of genomic biomarkers.
   

Based on therapeutic area, the biomarker discovery outsourcing services market is segmented into oncology, cardiology, neurology, autoimmune diseases, and other therapeutic areas. The oncology segment dominated the market with the largest revenue of USD 4.8 billion in 2024 and is expected to grow at a CAGR of 12% over the forecast period.
 

• Increase in cancer cases around the world is creating a greater need for early detection, accurate diagnosis, and effective therapies. For example, the World Health Organization stated that in 2022, around 20 million new cancer cases were recorded globally, resulting in approximately 9.7 million deaths. These high cancer incidence and death rates are driving the growth of this segment.
   
• The development of new technologies for metabolomics, transcriptomics, proteomics, and genomics have changed the field of cancer biomarker detection, therefore positively impacting the growth of the segment during the projection period.
   

Based on end use, the biomarker discovery outsourcing services market is segmented into pharmaceutical companies, biotechnology companies, and other end users. The biotechnology companies segment dominated the market with the largest revenue of USD 6.7 billion in 2024 and is expected to grow at a CAGR of 12.5% over the forecast period.
 

• The focus of biotechnology companies is shifting towards drug discovery and development, which requires biomarker-centric methodologies. It allows biotech companies to focus on their strengths and pass on certain responsibilities to external specialists and consultants.
   
• Moreover, while maintaining such equipment, infrastructure, and in-house teams is expensive, these outsourced services are cost-effective. These conditions are motivating biotechnology companies to utilize the consultants’ expertise, consequently boosting the growth of the segment.
   

The U.S. biomarker discovery outsourcing services market is projected to grow significantly, reaching USD 18.5 billion by 2034.
 

• The U.S. has significant revenue share owing to its growing biotech industry, regulatory expertise, and advanced healthcare infrastructure and technologies.
   
• In addition, the U.S. FDA has robust mechanisms for regulating biomarkers in the development of diagnostics and drugs. This paradigm reinforces biomarker validation and research projects in the area significantly.
   

The biomarker discovery outsourcing services market in the UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The NHS and the UK government embrace biomarker precision medicine and fund initiatives like Genomics England and the UK Biobank. Growth in funding from these institutions increases the outsourcing of biomarker research by biotech companies in the region.
   
• In addition, the country has a well-established bioinformatics and AI industry that serves computer-aided biomarker discovery. Third-party vendors apply big data, ML, and AI technologies for biomarker validation and identification, which further aids market growth.
   

Japan biomarker discovery outsourcing services market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan's aging population results in increasing rates of chronic diseases such as cancer, heart disease, and diabetes. For example, The World Health Organization (WHO) reported in 2023 that 29.1 The percent of the population in Japan aged 65 years or older is the highest in the world. This particular demographic points to a sustained increase in the demand for advanced services in biomarker discovery outsourcing over the forecast years.
   
• Japan’s increasing adoption of personalized medicine to customize treatments for specific patients is another factor driving growth in the market.
   

The biomarker discovery outsourcing services market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Increase in the number of chronic diseases like diabetes exhibits the requirement for developing personalized medicine biomarkers and technologies promoting timely disease diagnosis in Saudi Arabia. For example, a projection by Statista suggests that by 2026, 24.3 percent of adults in Saudi Arabia will be diagnosed with diabetes.
   
• Moreover, programs like Vision 2030 by the Saudi government focuses on the growth of the healthcare industry which includes biotechnology and medical research, further aiding to the market growth.
   

Biomarker Discovery Outsourcing Services Market Share

The market is concentrated and extremely competitive for both the large and smaller companies in the industry. The top 5 companies including ICON, Parexel International (MA) Corporation, Evotec, Bio-Rad Laboratories, and Frontage Laboratories shares about 40% of the market. These companies are focusing on investing in the advanced development of services such as ML and AI biomarker detection and single-cell Omics for improving treatment efficacy.
 

These companies are establishing strategic alliance agreements with research institutions and healthcare providers, which is helping with modern technology integration and greater distribution to meet the rising service demand. Their regulatory policies are also facilitating and promoting innovation and subsequent market entry, which is resulting in the consolidation of the firm's position in the growing market.
 

Biomarker Discovery Outsourcing Services Industry News:

• In June 2022, Healiva, a provider of precision medicine for acute and chronic wounds, announced the acquisition of two innovative wound cell therapy assets from Smith and Nephew. The acquisition allowed Healiva to create a personalized, comprehensive portfolio of cost-effective wound care technologies.
   
• In October 2024, Mölnlycke Health Care, a company focused on advanced wound care management, reported the acquisition of P.G.F. Industry Solutions GmbH, a company based in Austria that provided moistening and cleansing solutions for wounds. This acquisition will help enhance the Granudacyn brand and expand the wound care products portfolio of Mölnlycke Health Care.
   
• In May 2024, REPROCELL announced that its subsidiary Bioserve Biotechnologies underwent a distribution partnership with RISVI Trading, based in Qatar. The strategic partnership is aimed at enabling Bioserve to expand their distribution network for molecular biology products.
   
• In November 2024, Frontage Laboratories and Medicover Integrated Clinical Services announced that they have formed a strategic partnership which aims to expand the global visibility of both companies and facilitate better support for multicultural clinical trials as well as clinical laboratory services.
   

Biomarker Discovery Outsourcing Services Market Companies

Some of the eminent market participants operating in the biomarker discovery outsourcing services industry include:

• Almac Group Limited
• Biomcare ApS
• Bio-Rad Laboratories
• Crown Bioscience
• Evotec
• Excelra
• Frontage Labs
• ICON
• Integrated DNA Technologies
• Parexel International (MA) Corporation
• RayBiotech
• REPROCELL
• Sino Biological
• Svar Life Science

• ICON has expertise in clinical trials, that ensures seamless biomarker translation during research and development process. Additionally, the company leverages its data analytics capabilities such as AI driven insights during discovery process to ensure productive outcomes.
   
• Parexel International (MA) Corporation leverages its expertise in ensuring adherence to regulatory requirements and offers tailored biomarker strategies that significantly helps to ensure compliance during clinical trials and product approval stages.
   
• Proprietary AI platform of Evotec, PanHunter, offers integrated multi-omics data that accelerates biomarker discovery. Additionally, the company has established global networks with academic institutes and pharmaceutical companies, which supports in biomarker research and development.
   

The biomarker discovery outsourcing services market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Predictive biomarkers
• Prognostic biomarkers
• Safety biomarkers
• Surrogate endpoints
• Other types

Market, By Service

• Genomics biomarker services
• Proteomics biomarker services
• Bioinformatics biomarker services
• Other biomarker services

Market, By Therapeutic Area

• Oncology
• Cardiology
• Neurology
• Autoimmune diseases
• Other therapeutic areas

Market, By End Use

• Pharmaceutical companies
• Biotechnology companies
• Other end users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE